Researchers have confirmed that a once-weekly HIV medication works just as well as daily pills at suppressing the virus, according to a global study presented at the International AIDS Society conference. The findings open a new treatment option for people living with HIV who struggle with daily pill adherence.
The study compared lenacapavir, an injectable capsid inhibitor given once weekly, against standard daily oral antiretroviral therapy. Participants across multiple countries maintained viral suppression equally well on both regimens. The research represents a significant shift in how HIV treatment can be delivered.
Adherence remains one of the biggest challenges in HIV care. Missing doses allows the virus to replicate and develop resistance to medications. A once-weekly option removes the daily burden that can interfere with work, travel, and personal routines. For some people, this flexibility transforms HIV from a condition requiring constant daily attention into one managed with a single weekly dose.
The weekly formulation belongs to a newer class of HIV drugs targeting different parts of the virus's life cycle. Lenacapavir blocks the capsid protein, which the virus needs to complete its replication process. This mechanism differs from older antiretrovirals, meaning it works effectively even against some drug-resistant strains.
Healthcare providers emphasize that this study matters beyond just convenience. People with better adherence experience better health outcomes and lower transmission risk. When treatment fits into someone's life more easily, they're more likely to stick with it long-term.
The findings come as global health organizations work to end HIV as a public health emergency. Access to effective treatment that fits people's actual lives, rather than requiring strict daily routines, accelerates progress toward that goal.
Regulatory approval processes will determine how quickly this option becomes available in different countries. For people weighing treatment choices with their doctors, a once-weekly option now joins the existing arsenal of daily pills and other formulations as